Last week, Pfizer Inc. and Trillium Therapeutics Inc. announced an agreement for Pfizer to acquire all of Trillium’s outstanding shares for $18.50 per share. Trillium is a company developing innovative therapies for cancer treatment. Pfizer believes the proposed acquisition will strengthen its position in toncology by adding next-generation, investigational immuno-therapeutics to treat hematological malignancies, as well as biologics designed to enable a patient’s immune system to identify and destroy cancer cells. The transaction remains subject to Trillium shareholder and regulatory approval.